



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number:	09/899,780
		Filing Date:	July 5, 2001
		First Named Inventor:	Gary W. Wood
		Group Art Unit:	1642
Examiner Name:	Not yet assigned Atana M. Harris		
Attorney Docket Number:	70012590-04		
Sheet	2	of	2

OTHER REFERENCES – NON PATENT LITERATURE DOCUMENTS AND INFORMATION			
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
am		David N. Liebowitz, M.D., Ph.D., and Carl H. June, M.D., "Recent Advances in Adoptive Immunotherapy," <i>American Society of Clinical Oncology</i> , 1092-9118/99:302-312 (1999).	
		Gregory E. Plautz, M.D. <i>et al.</i> , "Systemic T Cell Adoptive Immunotherapy of Malignant Gliomas," <i>J Neurosurg.</i> , 89:42-51 (1998).	
		Alfred E. Chang and Suyu Shu, "Current Status of Adoptive Immunotherapy of Cancer," <i>Crit. Rev. Oncol. Hem.</i> , 22:213-228 (1996).	
		Alfred E. Chang <i>et al.</i> , "Adoptive Immunotherapy With Vaccine-Primed Lymph Node Cells Secondarily Activated With Anti-CD3 and Interleukin-2," <i>J. of Clin. Oncol.</i> , 15:796-807 (1997).	
		Jan B. Vermorken <i>et al.</i> , "Active Specific Immunotherapy for Stage II and Stage III Human Colon Cancer: a Randomised Trial," <i>The Lancet</i> , 353:345-350 (1999).	
		Alfred E. Change <i>et al.</i> , "Clinical Observations on Adoptive Immunotherapy With Vaccine-Primed T-Lymphocytes Secondarily Sensitized to Tumor in Vitro," <i>Can. Res.</i> , 53:1043-1050 (1993).	
		Frank P. Holladay <i>et al.</i> , "Autologous Tumor Cell Vaccination Combined With Adoptive Cellular Immunotherapy in Patients with Grade III/IV Astrocytoma," <i>J. Neuro.-Oncol.</i> , 27:179-189 (1996).	
		Stanley P. L. Leong <i>et al.</i> , "Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) and Autologous Melanoma Vaccine Mediate Tumor Regression in Patients with Metastatic Melanoma," <i>Journal of Immunotherapy</i> , 22(2):166-174 (1999).	
		Gregory E. Plautz <i>et al.</i> , "T-Cell Adoptive Immunotherapy of Metastatic Renal Cell Carcinoma," <i>Urology</i> , 54(4):617-624 (1999).	
		Maurizio Bendandi <i>et al.</i> , "Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma," <i>Nature Medicine</i> , 5:1171-1177 (1999).	
		Kruse and Beck, "Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours," <i>Biotechnol. Appl. Biochem.</i> , 25:197-205 (1997).	

Examiner Signature	Date Considered
<i>Atana M. Harris</i>	<i>January 13, 2003</i>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.